skip to Main Content

February 18, 2021
Nitrosamines and TB Medicines Information Note and Patient FAQs
Publication
In 2020, health authorities and drug manufacturers identified a type of chemical impurity called nitrosamines in rifampicin and rifapentine, two essential medicines used in the treatment and prevention of TB. TAG has developed several materials to help people affected by TB, advocates, policymakers, and implementers understand how the identification of…

February 16, 2021
Community Movements Across Africa, Asia and South America Celebrate Roll-Out of Short-Course, Patient-Friendly TB Preventive Therapy
Statement / Press
Advocates and affected communities working towards the global scale-up of short-course TB preventive therapy (TPT) hail the recent announcement of the launch of decently priced, patient-friendly fixed-dose combinations (FDC) of 3HP in five high burden HIV and TB countries.

January 21, 2021
Good COPs or Bad COPs: Promoting Interventions for Co-Infections and Advanced HIV Disease in 2021 PEPFAR Country Operational Plans (COPs)
Webinar / Presentation
On January 21, 2021, Treatment Action Group (TAG), Health GAP, and MSF Access Campaign presented this webinar on how to engage in PEPFAR COPs advocacy and promote the prioritization of interventions that address co-infections and advanced HIV disease.

December 11, 2020
2020 TAG Update
Publication
As we look forward to an end of an extremely challenging year—and past four years—we reflect on the remarkable resilience and impact of TAG, even and especially in these dark times.

December 7, 2020
2020 Report on TB Research Funding Trends
TB R&D Report
TAG’s latest report on global funding for TB research and development (R&D), published in collaboration with the Stop TB Partnership, presents new data on TB R&D funding in 2019 and analyzes trends in funding since 2005.

November 11, 2020
TAGline November 2020
TAGline
‘The Struggle of a Lifetime’ (Continued): The words of the late Honorable John Lewis ring powerfully true today. In the U.S., as we welcome a new President-elect and Vice President-elect, we must also defend democracy to ensure a complete, peaceful transition of power. We engage in the struggles generations before…

November 9, 2020
Treatment Action Group and AVAC Statement on Pfizer/BioNTech COVID-19 Vaccine Efficacy Announcement
Statement / Press
Treatment Action Group (TAG) and AVAC welcome today’s announcement that preliminary data from the efficacy trial of Pfizer/BioNTech’s mRNA COVID-19 vaccine indicates a high level of protection against COVID-19. Our organizations urge caution, however, given the very limited information that is available only through a company press release.

November 9, 2020
TAG Welcomes the Election of Joseph R. Biden Jr. and Kamala D. Harris
Statement / Press
Treatment Action Group (TAG) congratulates President-elect Joe Biden and Vice President-elect Kamala Harris on their ascension to the highest offices of the United States. Their victory in both the popular and electoral vote is historic.

November 9, 2020
Letter to Special Rapporteur on Cultural Rights
Letter / Comment
Our current letter follows an earlier letter dated June 23, 2020 and calls on the Special Rapporteur for cultural rights to explicitly acknowledge the human rights dimensions of science and reaffirm the right of everyone to participate in and enjoy the benefits of scientific progress and its applications in her…

October 21, 2020
Finally—A New Four-Month Treatment for Drug-Susceptible TB!
Statement / Press
Treatment Action Group (TAG) and the Community Research Advisors Group (CRAG) welcome the news of a safe and effective regimen for shortening tuberculosis (TB) treatment to just four months.

Back To Top